Incremental effects of antihypertensive drugs: instrumental variable analysis

Abstract

ObjectivesTo assess the incremental effects of adding extra antihypertensive drugs from a new class to a patient’s regimen.DesignInstrumental variable analysis of data from SPRINT (Systolic Blood Pressure Intervention Trial). To account for confounding by indication—when treatments seem less effective if they are administered to sicker patients—randomization status was used as the instrumental variable. Patients’ randomization status was either intensive (systolic blood pressure target <120 mm Hg) or standard (systolic blood pressure target <140 mm Hg) treatment. Results from instrumental variable models were compared with those from standard multivariable models.SettingSecondary data analysis of a randomized clinical trial conducted at 102 sites in 2010-15.Participants9092 SPRINT participants with hypertension and increased cardiovascular risk but no history of diabetes or stroke.Main outcomes measuresSystolic blood pressure, major cardiovascular events, and serious adverse events.ResultsIn standard multivariable models not adjusted for confounding by indication, addition of an antihypertensive drug from a new class was associated with modestly lower systolic blood pressure (−1.3 mm Hg, 95% confidence interval −1.6 to −1.0) and no change in major cardiovascular events (absolute risk of events per 1000 patient years, 0.5, 95% confidence interval −1.5 to 2.3). In instrumental variable models, the addition of an antihypertensive drug from a new class led to clinically important reductions in systolic blood pressure (−14.4 mm Hg, −15.6 to −13.3) and fewer major cardiovascular events (absolute risk −6.2, −10.9 to −1.3). Incremental reductions in systolic blood pressure remained large and similar in magnitude for patients already taking drugs from zero, one, two, or three or more drug classes. This finding was consistent across all subgroups of patients. The addition of another antihypertensive drug class was not associated with adverse events in either standard or instrumental variable models.ConclusionsAfter adjustment for confounding by indication, the addition of a new antihypertensive drug class led to large reductions in systolic blood pressure and major cardiovascular events among patients at high risk for cardiovascular events but without diabetes. Effects on systolic blood pressure persisted across all levels of baseline drug use and all subgroups of patients.

Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018

“…In some cases, a single drug might help reduce headaches and treat hypertension, a “dual effect” that makes it possible to treat 2 conditions with one drug. Even in patients already being treated with one antihypertensive drug, the addition of a second drug, perhaps to treat migraine, can still prove beneficial if blood pressure is not optimally managed …”

“…Even in patients already being treated with one antihypertensive drug, the addition of a second drug, perhaps to treat migraine, can still prove beneficial if blood pressure is not optimally managed. 24 Second, it seems possible though unproved that lowering blood pressure might reduce the risk of cardiovascular outcomes such as myocardial infarction or stroke. Migraine is associated with an increased risk of cardiovascular disease.…”

Sprint to work: A&nbsp;novel model for team science collaboration in academic medicine

“…While the sample is small and it is still early in the experiment, this process has proven to be more efficient than our old ways of writing papers. Of the eight manuscripts submitted, three are published [ 8 – 10 ], three received a revise and resubmit, and two are currently under review.…”

KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD

“…Additionally, most patients with CKD require triple antihypertensive therapy with an ACEI or ARB in addition to a CCB and diuretic, as a single pill combination or as individual pills. While polypharmacy is a commonly cited concern, an instrumental variable analysis by Markovitz et al 67 found incrementally lower SBP and cardiovascular risk with the addition of each additional antihypertensive agent in SPRINT.…”